These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20573077)

  • 21. Successful treatment of acquired C1 inhibitor deficiency with icatibant.
    Bright P; Dempster J; Longhurst H
    Clin Exp Dermatol; 2010 Jul; 35(5):553-4. PubMed ID: 20337653
    [No Abstract]   [Full Text] [Related]  

  • 22. Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.
    Prescrire Int; 2010 Nov; 19(110):245-7. PubMed ID: 21284353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
    Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
    Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches].
    Stehlin F; Ribi C
    Rev Med Suisse; 2020 Apr; 16(689):675-678. PubMed ID: 32270933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Home treatment of hereditary angioedema with icatibant administered by health care professionals.
    Farkas H; Csuka D; Zotter Z; Varga L; Böröcz Z; Temesszentandrási G; Jakab L; Karádi I
    J Allergy Clin Immunol; 2012 Mar; 129(3):851-852.e2. PubMed ID: 22154383
    [No Abstract]   [Full Text] [Related]  

  • 26. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.
    Campos RA; Valle SO; França AT; Cordeiro E; Serpa FS; Mello YF; Malheiros T; Toledo E; Mansour E; Fusaro G; Grumach AS
    Sao Paulo Med J; 2014; 132(5):261-5. PubMed ID: 25054967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema.
    Caballero T; Maurer M; Longhurst HJ; Aberer W; Bouillet L; Fabien V;
    J Investig Allergol Clin Immunol; 2016; 26(6):383-386. PubMed ID: 27996949
    [No Abstract]   [Full Text] [Related]  

  • 28. In brief: icatibant (Firazyr) for hereditary angioedema.
    Medical Letter
    Med Lett Drugs Ther; 2011 Nov; 53(1378):96. PubMed ID: 22113125
    [No Abstract]   [Full Text] [Related]  

  • 29. Management of acute attacks of hereditary angioedema: potential role of icatibant.
    Longhurst HJ
    Vasc Health Risk Manag; 2010 Sep; 6():795-802. PubMed ID: 20859548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinin formation in C1 inhibitor deficiency.
    Kaplan AP; Joseph K
    J Allergy Clin Immunol; 2010 Jun; 125(6):1411-2; author reply 1412. PubMed ID: 20381848
    [No Abstract]   [Full Text] [Related]  

  • 31. New Treatments for Hereditary Angioedema.
    Johnson NM; Phillips MA
    Skin Therapy Lett; 2018 Jan; 23(1):6-8. PubMed ID: 29357215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful perioperative management of a patient with C1 esterase inhibitor deficiency with a novel bradykinin receptor B2 antagonist.
    Senaratne KT; Cottrell AM; Prentice RI
    Anaesth Intensive Care; 2012 May; 40(3):523-6. PubMed ID: 22577920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Icatibant for the treatment of hereditary angioedema.
    Cole SW; Lundquist LM
    Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema.
    Wang Y; Jomphe C; Marier JF; Martin P
    J Clin Pharmacol; 2021 Apr; 61(4):555-564. PubMed ID: 33091166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema.
    Angeletti C; Angeletti PM; Mastrobuono F; Pilotti L; Ciccozzi A; Guetti C
    Int J Immunopathol Pharmacol; 2014; 27(4):653-9. PubMed ID: 25572747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study.
    Javaud N; Gompel A; Bouillet L; Boccon-Gibod I; Cantin D; Smaiti N; Carpentier F; Boubaya M; Launay D; Adnet F; Fain O
    Ann Allergy Asthma Immunol; 2015 Jun; 114(6):499-503. PubMed ID: 25935434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema.
    Maurer M; Aberer W; Caballero T; Bouillet L; Grumach AS; Botha J; Andresen I; Longhurst HJ;
    Clin Exp Allergy; 2022 Sep; 52(9):1048-1058. PubMed ID: 35861129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
    Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
    Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Icatibant.
    Deeks ED
    Drugs; 2010; 70(1):73-81. PubMed ID: 20030426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings.
    Grumach AS; Longhurst HJ; Aberer W; Bouillet L; Caballero T; Bygum A; Zanichelli A; Botha J; Andresen I; Maurer M;
    J Allergy Clin Immunol Pract; 2019 Mar; 7(3):1078-1080. PubMed ID: 30170163
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.